Get the Stockscreener App
1.94
6.01%
0.11
After Hours:
1.82
-0.12
-6.19%
Polyrizon Ltd stock is traded at $1.94, with a volume of 200.69K.
It is up +6.01% in the last 24 hours and up +65.81% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$1.83
Open:
$1.8
24h Volume:
200.69K
Relative Volume:
0.08
Market Cap:
$8.14M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.29%
1M Performance:
+65.81%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.7301
$1.98
1-Week Range:
$1.7301
$2.80
52-Week Range:
$0.77
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.94 | 8.14M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Polyrizon Ltd Stock (PLRZ) Latest News
Polyrizon (PLRZ) Stock Climbs After Patent Publication Update - Stocks Telegraph
Polyrizon Shares Rise After Publication of National Patent Application - MarketWatch
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today? - Benzinga
Patents and new EV’s have these small caps perking - RagingBull
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - The Manila Times
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
Full Stock Market News from 2024-12-21 - StockTitan
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com India
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial - MSN
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs - The Manila Times
Polyrizon Strengthens Clinical Leadership Ahead of Key 2025 PL-14 Trial, Appoints Regulatory Expert - StockTitan
U.S. Stocks Drop Sharply with Losses Across Major Sectors, Amazon and American Express Lead Declines - mediahousepress
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com India
Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus.com
TFSA: 3 Top TSX Stocks for Your $7,000 Contribution - Yahoo Canada Finance
Wall Street-Heavily Traded - WDRB
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Strategic DealSends Polyrizon (PLRZ) Shares To New Heights - Stocks Telegraph
Stellantis moves up launch of hybrid Ramcharger as EV demand cools - Yahoo Canada Finance
Polyrizon Shares Surge on Impending Clinical Trial - MarketWatch
What's Going On With Polyrizon Shares Wednesday?Polyrizon (NASDAQ:PLRZ) - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Biotechs and nuclear power for AI in play today 📈 - RagingBull
Artificial Intelligence (AI) News Live Feed - StockTitan
Polyrizon's Moving Forward with Expected 2025 Clinical TrialEntered Manufacturing Agreement for its PL-14 Allergy Blocker - The Manila Times
Polyrizon Partners with EU Manufacturing Giant for Novel Allergy Blocker Clinical Production - StockTitan
OPEC+ wary of renewed US oil output rise under Trump, sources say - Yahoo Canada Finance
Oil sags on soft Chinese spending, investor pause before US Fed rate move - Yahoo Canada Finance
Federal Reserve is likely to slow its rate cuts with inflation pressures still elevated - Yahoo Canada Finance
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Yahoo Canada Finance
Notre Dame Cathedral's reopening spectacle capped a stellar year for luxury house LVMH - Yahoo Canada Finance
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance - The Manila Times
Polyrizon Strengthens Leadership Team with Key Regulatory Affairs VP Appointment from Eurofins - StockTitan
What do we know about the mysterious drones reported flying over New Jersey? - Yahoo Canada Finance
3 No Brainer Tech Stocks to Buy With $500 Right Now - Yahoo Canada Finance
Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker - TipRanks
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - The Manila Times
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker - The Bakersfield Californian
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - GlobeNewswire Inc.
Polyrizon Partners with Eurofins for Clinical Trial Manufacturing of PL-14 Allergy Blocker - StockTitan
Polyrizon Ltd.’s Quiet Period To End on December 9th (NASDAQ:PLRZ) - Defense World
Polyrizon Ltd Stock (PLRZ) Financials Data
There is no financial data for Polyrizon Ltd (PLRZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.60%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):